Cellectis S.A.

AI-generated fair value estimate for this company.

Method: Net cash per share ($86.3M net cash = $166.7M cash & short-term investments less $80.4M debt/lease obligations, / 72.70M shares = $1.19) plus risk-adjusted NPV of (a) the existing licensing/royalty revenue stream (TTM revenue $63.8M, modeled as a 40%-margin annuity declining 20%/yr for 5 years at a 15% discount rate, ~=$49M) and (b) the new preclinical in-vivo gene-editing platform (.HEAL-101/.HEAL-201) assuming $1B peak sales potential, 5% probability of reaching market over a 10-year horizon, 30% margins and a 15% discount rate (~=$14M); total equity value ~$149.5M / 72.70M shares ~= $2.05/share (market cap $100.4M, price $1.43).

Reasoning: Cellectis discontinued its internal UCART cell-therapy pipeline in Sept 2026 to pivot to an unproven preclinical in-vivo editing platform, so most of its prior clinical-stage pipeline no longer has standalone value; a net-cash-plus-heavily-discounted-optionality approach fits this distressed, post-pivot, pre-revenue-model-reset situation better than a standard DCF or rNPV on the abandoned programs.